Journal profile · Oncology
Cancer Epidemiology
ISSN 1877-7821 · eISSN 1877-783X · Elsevier BV · ENGLAND · Bimonthly · Founded 2009
Cancer Epidemiology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.97; hybrid open access; APC about USD 3,740; median 92 days to acceptance (105 articles, last 24 months); 202 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Epidemiology is published by Elsevier BV and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Global Cancer Incidence and Screening, Cancer Risks and Factors and Colorectal Cancer Screening and Detection, together about 38.2% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer determinants, prevention, prognosis and outcomesCancer Epidemiology publishes original research, prioritizing studies that contribute new information about cancer causes, prevention and control. As such, the journal's scope covers all aspects of cancer epidemiology including studies of:• Risk factors for cancer initiation, development, and prognosis • Early detection, prevention, and screening • Survivorship • Descriptive patterns and trends • MethodologyCancer Epidemiology welcomes original articles, reviews (systematic and critical), meta-analyses, invited editorials and commentaries, as well as letters to the editor commenting on research previously published in the journal.Cancer Epidemiology (Cancer Epidemiol.) is indexed and abstracted in: MEDLINE/PubMed, Current Contents/Clinical Medicine, the Science Citation Index Expanded, and Thomson Reuters Journal Citation Reports (Science Edition).
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Frederic SitasPublisher website
Editorial board by country: 3 in mainland China (about 6%); most named United Kingdom 9, Australia 9, United States 8, France 6, Mainland China 3 (50 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Global Cancer Incidence and ScreeningMedicine22.7%
- Cancer Risks and FactorsMedicine8%
- Colorectal Cancer Screening and DetectionMedicine7.5%
- Multiple and Secondary Primary CancersMedicine5.1%
- Cervical Cancer and HPV ResearchMedicine5.1%
- Acute Lymphoblastic Leukemia researchMedicine4.8%
- Head and Neck Cancer StudiesMedicine4.2%
- Childhood Cancer Survivors' Quality of LifeMedicine3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Public, Environmental & Occupational Health | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Public, Environmental & Occupational Health | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Public, Environmental & Occupational Health | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINECurrent ContentsPublisher website
Other: Thomson Reuters Journal Citation Reports (Science Edition)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.97LetPub ·
- Impact factor (publisher)
- 3Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- CiteScore (publisher)
- 4.6Publisher website ·
- SJR 2026-06
- 1.04LetPub ·
- SNIP 2026-06
- 1.07LetPub ·
- h-index
- 68LetPub ·
- h-index
- 96OpenAlex ·
- i10-index
- 1,643OpenAlex ·
- 2-year mean citedness
- 3.03OpenAlex ·
- Self-citation rate
- 3.3%LetPub ·
- Share of gold OA articles
- 39.21%LetPub ·
Volume
- Articles per year
- 186LetPub ·
Articles by year OpenAlex count · 3,090 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 219 | 110 | 65 |
| 2025 | 202 | 104 | 441 |
| 2024 | 179 | 92 | 1,310 |
| 2023 | 156 | 78 | 1,245 |
| 2022 | 194 | 90 | 2,066 |
| 2021 | 160 | 70 | 2,339 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
92 daysMedian, submission to acceptance · P25–P75 54 days – 121 days
- Acceptance to online
- median 7 days (105 articles)
- Submission to online
- median 99 days
- Sample
- 105 articles with submission and acceptance dates (485 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 68.75%LetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 54 daysPublisher website ·
- Submission to acceptance
- 87 daysPublisher website ·
- Acceptance to publication
- 8 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,740 / EUR 3,500 / GBP 2,990 / JPY 463,870 | — | — | |
| Publisher website | USD 3,690 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 300 words
- Keywords
- ≥ 1
- Manuscript length
- ≤ 3,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted14, with length limits
- commentaries and editorialsCommentaries and editorials: Authors who are considering submitting a commentary should contact the Editorial Office with a brief outline of the proposed contri…Length not stated
- commentaryCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- editorialCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- letterCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…main text ≤ 1,000 words
- letters to the editorCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- meta-analysisCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- original research articleCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- original research articlesOriginal Research Articles: Research articles which have not been published previously, except in a preliminary form, may be submitted as original full-length r…Length not stated
- research articleCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- research paperCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- reviewCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- review articleCancer Epidemiology will not consider manuscripts that have been supported either directly or indirectly by tobacco companies. Cancer Epidemiology accepts the f…Length not stated
- reviews and meta-analysesReviews and meta-analyses: Cancer Epidemiology welcomes reviews and meta-analyses that critically assess topical fields, particularly those that include the aut…Length not stated
- short reports/communicationsShort reports/communications: Should provide a brief but complete account of an original piece of work. Short reports must contain a structured abstract of 150-…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Authorship
By adhering to the authorship requirements stated above, authors meet the International Committee of Medical Journal Editors (ICMJE) criteria [updated version January 2024] on authorship.
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
Manuscripts supported by tobacco companies are not considered. Model summary
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process. Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2009
- ISSN
- 1877-7821
- Electronic ISSN
- 1877-783X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Epidemiology
What CAS zone is Cancer Epidemiology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Epidemiology is in Zone 3 of Medicine, and in Zone 3 of the minor category Public, Environmental & Occupational Health / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Epidemiology?
The latest impact factor listed by LetPub is 2.97; CiteScore 4.6, h-index 96.
How long does peer review take at Cancer Epidemiology?
Based on the dates recorded on 105 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 92 days (interquartile range 54–121 days); authors report an average review time of about 2 months. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Epidemiology?
According to the journal's author guidelines: Abstract: ≤ 300 words; Keywords: ≥ 1; Manuscript length: ≤ 3,000 words; Reference style: Numbered, in order of citation; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Epidemiology based?
Of the 50 board members whose country the journal's board page names, 3 (about 6%) are in mainland China; the countries named most often are United Kingdom (9), Australia (9) and United States (8). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Epidemiology?
According to LetPub and DOAJ records, Cancer Epidemiology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE and Current Contents; that list has not been checked against each database.
Is Cancer Epidemiology open access, and what is the APC?
Cancer Epidemiology is a hybrid journal. For open-access publication: APC about USD 3,740.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .